tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Nicole Germino, 34 are a BUY (94.44%), 2 are a HOLD (5.56%).
Analyst Nicole Germino, currently employed at TRUIST, carries an average stock price target met ratio of 55.21% that have a potential upside of 58.98% achieved within 203 days.
Nicole Germino’s has documented 67 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on YMAB, Y mAbs Therapeutics at 05-Aug-2025.
Analyst best performing recommendations are on INSM (INSMED).
The best stock recommendation documented was for INSM (INSMED) at 5/16/2024. The price target of $48 was fulfilled within 12 days with a profit of $22.9 (91.24%) receiving and performance score of 76.03.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Oct-2019
$45
$8.4 (22.95%)
$45
Buy Since 25-Mar-2025
$43
$6.4 (17.49%)
$43
Buy Since 18-Aug-2025
$50
$13.4 (36.61%)
$50
Buy Since 10-Dec-2025
$62
$25.4 (69.40%)
$35
What Year was the first public recommendation made by Nicole Germino?
